CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
6.14
0%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 6.14
Open 6.14
1-Year Change -3.61%
Day's Range 6.09 - 6.2
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 25, 2024 6.13 0.13 2.17% 6.00 6.30 5.98
Jul 24, 2024 6.14 0.01 0.16% 6.13 6.30 6.13
Jul 23, 2024 6.26 -0.02 -0.32% 6.28 6.31 6.15
Jul 22, 2024 6.29 0.21 3.45% 6.08 6.33 6.03
Jul 19, 2024 6.07 0.09 1.51% 5.98 6.12 5.91
Jul 18, 2024 6.04 -0.04 -0.66% 6.08 6.29 5.87
Jul 17, 2024 6.19 0.08 1.31% 6.11 6.22 6.09
Jul 16, 2024 6.19 0.19 3.17% 6.00 6.22 6.00
Jul 15, 2024 5.99 0.25 4.36% 5.74 6.05 5.74
Jul 12, 2024 5.90 0.10 1.72% 5.80 5.93 5.74
Jul 11, 2024 5.78 0.43 8.04% 5.35 5.87 5.35
Jul 10, 2024 5.19 -0.12 -2.26% 5.31 5.34 5.11
Jul 9, 2024 5.29 0.10 1.93% 5.19 5.32 5.17
Jul 8, 2024 5.24 -0.01 -0.19% 5.25 5.36 5.21
Jul 5, 2024 5.20 -0.06 -1.14% 5.26 5.29 5.14
Jul 3, 2024 5.22 -0.03 -0.57% 5.25 5.40 5.22
Jul 2, 2024 5.23 -0.32 -5.77% 5.55 5.56 5.19
Jul 1, 2024 5.56 -0.05 -0.89% 5.61 5.76 5.55
Jun 28, 2024 5.62 -0.19 -3.27% 5.81 5.81 5.42
Jun 27, 2024 5.80 0.08 1.40% 5.72 5.90 5.72

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vanda Company profile

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vanda Pharmaceuticals Inc. revenues increased 8% to $268.7M. Net income increased 42% to $33.2M. Revenues reflect Hetlioz segment increase of 8% to $173.5M, Fanapt segment increase of 9% to $95.1M. Net income benefited from Selling, General and administrative - decrease of 10% to $105.9M (expense), Advertising Expenses decrease of 47% to $6.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 150M auth., 28,103,441 issd. Insiders own 1.56%. 4/18/06 IPO: 5.8M shs. @ $10 per shareby JP Morgan Securities, Inc.

Industry: Bio Therapeutic Drugs

Suite 300E
2200 Pennsylvania Ave Nw
WASHINGTON
WASHINGTON DC 20037
US

People also watch

XRP/USD

0.61 Price
+1.640% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

67,928.50 Price
+3.990% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,029.00 Price
+1.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,281.07 Price
+4.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading